CET019

CET019 is a novel small molecule inhibitor developed by Oregon Health & Science University (OHSU) and Stanford University for the treatment of triple-negative breast cancer (TNBC). It acts as a ribosomal protein modulator, targeting ribosomal proteins (including large subunit ribosomal proteins [RPLs] and small subunit ribosomal proteins [RPS]) to disrupt protein translation pathways. In preclinical studies, CET019 has demonstrated the ability to suppress the clonogenic potential and growth of various TNBC cell lines, induce G2/M phase cell cycle arrest, and inhibit tumor growth kinetics and lung metastasis in mouse xenograft and patient-derived xenograft (PDX) models.